Michael Graner
Concepts (405)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Extracellular Vesicles | 7 | 2022 | 83 | 3.150 |
Why?
| Exosomes | 11 | 2020 | 92 | 2.870 |
Why?
| Glioma | 10 | 2019 | 285 | 2.830 |
Why?
| Cancer Vaccines | 15 | 2018 | 137 | 2.100 |
Why?
| Brain Neoplasms | 12 | 2022 | 966 | 2.040 |
Why?
| Molecular Chaperones | 16 | 2013 | 156 | 2.020 |
Why?
| Neoplasms | 10 | 2021 | 2086 | 1.540 |
Why?
| Multiple Sclerosis | 8 | 2023 | 372 | 1.420 |
Why?
| Tumor Microenvironment | 3 | 2019 | 428 | 1.130 |
Why?
| Cytokines | 5 | 2021 | 1824 | 1.110 |
Why?
| Antigens, Neoplasm | 7 | 2018 | 222 | 1.090 |
Why?
| Glioblastoma | 4 | 2022 | 250 | 1.080 |
Why?
| Immunoglobulin G | 7 | 2023 | 766 | 1.010 |
Why?
| Unfolded Protein Response | 3 | 2016 | 44 | 1.000 |
Why?
| HSP90 Heat-Shock Proteins | 4 | 2015 | 43 | 0.980 |
Why?
| Immune Tolerance | 2 | 2018 | 321 | 0.960 |
Why?
| Oligoclonal Bands | 4 | 2022 | 21 | 0.920 |
Why?
| HSP70 Heat-Shock Proteins | 6 | 2015 | 61 | 0.910 |
Why?
| Stroke | 2 | 2023 | 1019 | 0.880 |
Why?
| Proteome | 5 | 2014 | 337 | 0.870 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 1142 | 0.850 |
Why?
| Heat-Shock Proteins | 6 | 2013 | 112 | 0.830 |
Why?
| Ischemic Attack, Transient | 1 | 2023 | 62 | 0.790 |
Why?
| Antineoplastic Agents | 7 | 2021 | 1875 | 0.760 |
Why?
| Meningioma | 1 | 2022 | 76 | 0.730 |
Why?
| Extracellular Space | 4 | 2015 | 116 | 0.730 |
Why?
| Meningeal Neoplasms | 1 | 2022 | 86 | 0.730 |
Why?
| Immunity | 3 | 2018 | 121 | 0.680 |
Why?
| Astrocytes | 2 | 2019 | 159 | 0.670 |
Why?
| Brain Ischemia | 1 | 2023 | 297 | 0.660 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2019 | 12 | 0.640 |
Why?
| Antigen Presentation | 4 | 2018 | 188 | 0.640 |
Why?
| Proteomics | 5 | 2020 | 815 | 0.630 |
Why?
| Immunomodulation | 2 | 2018 | 84 | 0.630 |
Why?
| Neoplasm Proteins | 2 | 2016 | 385 | 0.620 |
Why?
| Cell Line, Tumor | 17 | 2018 | 2698 | 0.610 |
Why?
| RNA, Neoplasm | 1 | 2018 | 80 | 0.600 |
Why?
| MicroRNAs | 3 | 2018 | 600 | 0.580 |
Why?
| T-Lymphocytes | 4 | 2018 | 1735 | 0.570 |
Why?
| Brain Injuries | 1 | 2021 | 459 | 0.530 |
Why?
| Signal Transduction | 8 | 2020 | 4501 | 0.500 |
Why?
| Cell Proliferation | 7 | 2018 | 2173 | 0.490 |
Why?
| Animals | 40 | 2023 | 31565 | 0.480 |
Why?
| Calreticulin | 2 | 2013 | 24 | 0.480 |
Why?
| Humans | 55 | 2023 | 114039 | 0.440 |
Why?
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.430 |
Why?
| Dog Diseases | 1 | 2013 | 41 | 0.420 |
Why?
| Leukocytes, Mononuclear | 1 | 2015 | 489 | 0.420 |
Why?
| Heat-Shock Response | 2 | 2015 | 46 | 0.410 |
Why?
| Mice, Inbred BALB C | 13 | 2014 | 1144 | 0.410 |
Why?
| Autoantibodies | 1 | 2020 | 1347 | 0.400 |
Why?
| Cerebellar Neoplasms | 1 | 2012 | 130 | 0.360 |
Why?
| Stress, Physiological | 1 | 2013 | 379 | 0.350 |
Why?
| Medulloblastoma | 1 | 2012 | 172 | 0.350 |
Why?
| Mice | 24 | 2023 | 14841 | 0.350 |
Why?
| Transcription Factors | 2 | 2014 | 1525 | 0.340 |
Why?
| Drug Resistance, Neoplasm | 2 | 2013 | 636 | 0.330 |
Why?
| Mycobacterium tuberculosis | 7 | 2015 | 269 | 0.320 |
Why?
| Tuberculosis | 4 | 2015 | 241 | 0.310 |
Why?
| Dendritic Cells | 11 | 2008 | 435 | 0.300 |
Why?
| Carrier Proteins | 2 | 2009 | 694 | 0.290 |
Why?
| Interleukin-6 | 4 | 2023 | 673 | 0.280 |
Why?
| Histocompatibility Antigens Class I | 3 | 2018 | 170 | 0.270 |
Why?
| Isoelectric Focusing | 3 | 2015 | 33 | 0.270 |
Why?
| Neoplasms, Experimental | 3 | 2006 | 149 | 0.270 |
Why?
| Immunotherapy | 3 | 2021 | 473 | 0.260 |
Why?
| Case-Control Studies | 5 | 2021 | 3003 | 0.260 |
Why?
| Lymphocyte Activation | 4 | 2012 | 1036 | 0.260 |
Why?
| Interferon-gamma | 8 | 2015 | 719 | 0.250 |
Why?
| Cell Movement | 6 | 2018 | 863 | 0.250 |
Why?
| Peptides | 4 | 2022 | 848 | 0.250 |
Why?
| Oligopeptides | 4 | 2007 | 234 | 0.250 |
Why?
| Amino Acid Sequence | 6 | 2020 | 1981 | 0.230 |
Why?
| Female | 28 | 2023 | 59321 | 0.230 |
Why?
| Albumins | 1 | 2004 | 89 | 0.230 |
Why?
| Fusion Proteins, bcr-abl | 4 | 2007 | 60 | 0.230 |
Why?
| Integrins | 3 | 1998 | 79 | 0.220 |
Why?
| Leukemia, B-Cell | 2 | 2000 | 11 | 0.220 |
Why?
| Multiple Sclerosis, Chronic Progressive | 1 | 2023 | 25 | 0.220 |
Why?
| Neuroblastoma | 2 | 2023 | 133 | 0.210 |
Why?
| Lung Neoplasms | 2 | 2013 | 2159 | 0.210 |
Why?
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2023 | 69 | 0.210 |
Why?
| Membrane Glycoproteins | 4 | 2015 | 429 | 0.200 |
Why?
| Drosophila Proteins | 3 | 1998 | 164 | 0.200 |
Why?
| Transferases | 1 | 2022 | 28 | 0.200 |
Why?
| Tuberculosis, Pleural | 2 | 2014 | 6 | 0.200 |
Why?
| Tuberculosis, Pulmonary | 3 | 2012 | 113 | 0.200 |
Why?
| Organ Specificity | 2 | 2020 | 266 | 0.190 |
Why?
| Middle Aged | 13 | 2023 | 26601 | 0.190 |
Why?
| Apoptosis | 3 | 2023 | 2349 | 0.190 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2013 | 695 | 0.190 |
Why?
| Peptide Fragments | 4 | 2020 | 665 | 0.190 |
Why?
| Epitopes | 2 | 2020 | 434 | 0.190 |
Why?
| Tissue Plasminogen Activator | 1 | 2023 | 204 | 0.180 |
Why?
| Blotting, Western | 4 | 2009 | 1143 | 0.180 |
Why?
| Cell Extracts | 3 | 2006 | 15 | 0.180 |
Why?
| Immunosuppressive Agents | 1 | 2004 | 641 | 0.180 |
Why?
| Laser Capture Microdissection | 1 | 2020 | 23 | 0.180 |
Why?
| Ultracentrifugation | 1 | 2020 | 46 | 0.180 |
Why?
| Extracellular Matrix Proteins | 2 | 1998 | 126 | 0.180 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2012 | 959 | 0.170 |
Why?
| Male | 18 | 2023 | 55392 | 0.170 |
Why?
| Prognosis | 2 | 2021 | 3315 | 0.170 |
Why?
| Plasma Cells | 1 | 2020 | 56 | 0.170 |
Why?
| Antibody Specificity | 1 | 2020 | 175 | 0.170 |
Why?
| Protein Transport | 2 | 2019 | 391 | 0.170 |
Why?
| Peptide Library | 1 | 2020 | 81 | 0.170 |
Why?
| Cells, Cultured | 6 | 2015 | 3861 | 0.160 |
Why?
| Epstein-Barr Virus Infections | 1 | 2020 | 72 | 0.160 |
Why?
| Nanoparticles | 2 | 2020 | 312 | 0.160 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2007 | 94 | 0.160 |
Why?
| Virus Latency | 1 | 2020 | 80 | 0.160 |
Why?
| Tumor Cells, Cultured | 6 | 2007 | 845 | 0.160 |
Why?
| Transcription, Genetic | 3 | 2014 | 1310 | 0.160 |
Why?
| Bacteriophages | 1 | 2020 | 75 | 0.160 |
Why?
| Lymphoma, B-Cell | 1 | 2000 | 87 | 0.160 |
Why?
| Receptors, Purinergic | 1 | 2018 | 20 | 0.160 |
Why?
| Tenascin | 1 | 1998 | 12 | 0.160 |
Why?
| Ovarian Neoplasms | 2 | 2017 | 386 | 0.150 |
Why?
| Receptors, Fc | 1 | 2018 | 45 | 0.150 |
Why?
| Laminin | 1 | 1998 | 69 | 0.150 |
Why?
| Alternative Splicing | 2 | 2006 | 186 | 0.150 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 924 | 0.150 |
Why?
| Antigen-Presenting Cells | 1 | 2018 | 150 | 0.150 |
Why?
| Leukemia | 3 | 2006 | 208 | 0.150 |
Why?
| DNA, Viral | 1 | 2020 | 349 | 0.150 |
Why?
| Milk | 1 | 2018 | 123 | 0.150 |
Why?
| DNA Methylation | 1 | 2022 | 493 | 0.150 |
Why?
| Drug Carriers | 1 | 2018 | 112 | 0.150 |
Why?
| Immune System | 1 | 2019 | 171 | 0.150 |
Why?
| Prostatic Neoplasms | 2 | 2015 | 913 | 0.140 |
Why?
| Cell Hypoxia | 2 | 2015 | 221 | 0.140 |
Why?
| Biological Transport | 1 | 2018 | 374 | 0.140 |
Why?
| Host-Pathogen Interactions | 1 | 2020 | 295 | 0.140 |
Why?
| Inflammation | 2 | 2019 | 2464 | 0.140 |
Why?
| Autoantigens | 1 | 2020 | 396 | 0.140 |
Why?
| Antigens, Bacterial | 2 | 2015 | 111 | 0.140 |
Why?
| Adenosine Triphosphate | 1 | 2018 | 428 | 0.130 |
Why?
| Herpesvirus 3, Human | 1 | 2020 | 377 | 0.130 |
Why?
| Mass Spectrometry | 2 | 2016 | 622 | 0.130 |
Why?
| Brain | 3 | 2020 | 2355 | 0.130 |
Why?
| Lymphocytes | 1 | 2017 | 327 | 0.130 |
Why?
| Neurons | 2 | 2022 | 1277 | 0.130 |
Why?
| Antigens, Surface | 1 | 2015 | 146 | 0.120 |
Why?
| Protein Array Analysis | 1 | 2015 | 55 | 0.120 |
Why?
| DNA | 1 | 2022 | 1350 | 0.120 |
Why?
| Sequence Analysis, RNA | 1 | 2017 | 388 | 0.120 |
Why?
| Aged | 6 | 2023 | 18969 | 0.120 |
Why?
| RNA, Messenger | 5 | 2020 | 2550 | 0.120 |
Why?
| Lung | 3 | 2017 | 3521 | 0.120 |
Why?
| Granuloma | 1 | 2015 | 82 | 0.120 |
Why?
| Alkynes | 1 | 2014 | 53 | 0.120 |
Why?
| Azides | 1 | 2014 | 46 | 0.120 |
Why?
| Acute Lung Injury | 1 | 2017 | 268 | 0.120 |
Why?
| Click Chemistry | 1 | 2014 | 48 | 0.110 |
Why?
| BCG Vaccine | 2 | 2010 | 18 | 0.110 |
Why?
| Intestinal Mucosa | 1 | 2018 | 532 | 0.110 |
Why?
| Flow Cytometry | 3 | 2012 | 1075 | 0.110 |
Why?
| Adherens Junctions | 1 | 2013 | 26 | 0.110 |
Why?
| Interferon-gamma Release Tests | 1 | 2014 | 26 | 0.110 |
Why?
| Mice, Inbred C57BL | 6 | 2017 | 4680 | 0.110 |
Why?
| Pleural Effusion | 1 | 2014 | 46 | 0.110 |
Why?
| Adult | 12 | 2023 | 30371 | 0.110 |
Why?
| Basigin | 1 | 2013 | 25 | 0.110 |
Why?
| Triglycerides | 1 | 2015 | 467 | 0.110 |
Why?
| Histocompatibility Antigens Class II | 2 | 2013 | 350 | 0.110 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2013 | 68 | 0.110 |
Why?
| Dacarbazine | 1 | 2013 | 99 | 0.110 |
Why?
| Lipogenesis | 1 | 2013 | 56 | 0.110 |
Why?
| Aged, 80 and over | 2 | 2023 | 6306 | 0.110 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2013 | 118 | 0.100 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2013 | 92 | 0.100 |
Why?
| Drosophila | 3 | 1998 | 133 | 0.100 |
Why?
| ErbB Receptors | 2 | 2006 | 554 | 0.100 |
Why?
| T-Lymphocytes, Cytotoxic | 6 | 2015 | 154 | 0.100 |
Why?
| Treatment Outcome | 3 | 2023 | 9049 | 0.100 |
Why?
| Liver | 2 | 2013 | 1633 | 0.100 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2012 | 13 | 0.100 |
Why?
| Neoplasm Grading | 1 | 2013 | 241 | 0.100 |
Why?
| Prostate | 1 | 2013 | 157 | 0.100 |
Why?
| Neutrophils | 1 | 2017 | 1089 | 0.100 |
Why?
| Transforming Growth Factor beta1 | 1 | 2013 | 153 | 0.100 |
Why?
| Tumor Burden | 1 | 2013 | 258 | 0.100 |
Why?
| Dogs | 1 | 2013 | 331 | 0.100 |
Why?
| B-Lymphocytes | 2 | 2022 | 762 | 0.100 |
Why?
| Epithelial Cells | 1 | 2017 | 946 | 0.100 |
Why?
| Phenotype | 3 | 2018 | 2784 | 0.100 |
Why?
| Gene Regulatory Networks | 1 | 2013 | 228 | 0.100 |
Why?
| Th17 Cells | 1 | 2012 | 58 | 0.100 |
Why?
| RNA-Binding Proteins | 1 | 2014 | 344 | 0.100 |
Why?
| Cell Line | 4 | 2020 | 2629 | 0.090 |
Why?
| B-Lymphocyte Subsets | 1 | 2012 | 68 | 0.090 |
Why?
| Mice, Nude | 3 | 2007 | 628 | 0.090 |
Why?
| Cell Survival | 2 | 2012 | 1014 | 0.090 |
Why?
| Oxygen | 1 | 2015 | 851 | 0.090 |
Why?
| Enzyme-Linked Immunospot Assay | 1 | 2010 | 34 | 0.090 |
Why?
| Radiography | 1 | 2013 | 803 | 0.090 |
Why?
| Interleukin-17 | 1 | 2011 | 104 | 0.090 |
Why?
| Transforming Growth Factor beta | 3 | 2011 | 445 | 0.090 |
Why?
| Immunity, Innate | 1 | 2015 | 720 | 0.090 |
Why?
| Immunohistochemistry | 3 | 2009 | 1624 | 0.080 |
Why?
| Receptors, Interleukin-6 | 1 | 2009 | 34 | 0.080 |
Why?
| Latent Tuberculosis | 1 | 2010 | 64 | 0.080 |
Why?
| Tissue Array Analysis | 1 | 2009 | 48 | 0.080 |
Why?
| Interleukins | 1 | 2011 | 236 | 0.080 |
Why?
| Mycobacterium bovis | 1 | 2009 | 11 | 0.080 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2008 | 103 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 787 | 0.080 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 127 | 0.080 |
Why?
| Cross-Priming | 1 | 2008 | 18 | 0.080 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 99 | 0.080 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 367 | 0.080 |
Why?
| Toll-Like Receptor 2 | 1 | 2009 | 110 | 0.080 |
Why?
| Antigens, Differentiation | 1 | 2008 | 79 | 0.080 |
Why?
| Carcinoma, Lewis Lung | 2 | 2005 | 13 | 0.080 |
Why?
| Blood-Brain Barrier | 1 | 2008 | 106 | 0.070 |
Why?
| Neoplasm Transplantation | 3 | 2006 | 227 | 0.070 |
Why?
| DNA-Binding Proteins | 1 | 2014 | 1311 | 0.070 |
Why?
| Hypoxia | 1 | 2013 | 956 | 0.070 |
Why?
| Biomarkers | 4 | 2023 | 3397 | 0.070 |
Why?
| Immunotherapy, Active | 1 | 2007 | 8 | 0.070 |
Why?
| Immunization | 3 | 2015 | 397 | 0.070 |
Why?
| Tissue Extracts | 1 | 2007 | 19 | 0.070 |
Why?
| Angiogenesis Inhibitors | 1 | 2008 | 213 | 0.070 |
Why?
| Tissue Distribution | 2 | 2018 | 285 | 0.070 |
Why?
| Cell Membrane | 1 | 2009 | 670 | 0.060 |
Why?
| Vitamin E | 1 | 2005 | 110 | 0.060 |
Why?
| T-Lymphocyte Subsets | 1 | 2007 | 383 | 0.060 |
Why?
| Spleen | 2 | 2004 | 485 | 0.060 |
Why?
| Immunotherapy, Adoptive | 2 | 2004 | 184 | 0.060 |
Why?
| Piperidines | 1 | 2005 | 159 | 0.060 |
Why?
| Integrin alpha Chains | 3 | 1998 | 22 | 0.060 |
Why?
| Disease Models, Animal | 1 | 2013 | 3498 | 0.060 |
Why?
| Quinazolines | 1 | 2005 | 240 | 0.060 |
Why?
| Central Nervous System Neoplasms | 1 | 2005 | 125 | 0.060 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2783 | 0.060 |
Why?
| Kinetics | 2 | 2006 | 1547 | 0.050 |
Why?
| Neoplasm Invasiveness | 2 | 2015 | 438 | 0.050 |
Why?
| Melanoma | 1 | 2008 | 620 | 0.050 |
Why?
| Head and Neck Neoplasms | 1 | 2006 | 427 | 0.050 |
Why?
| Piperazines | 1 | 2004 | 310 | 0.050 |
Why?
| Interleukin-12 | 3 | 2008 | 110 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2020 | 1228 | 0.050 |
Why?
| Survival Analysis | 2 | 2006 | 1206 | 0.050 |
Why?
| Carcinoma, Squamous Cell | 1 | 2006 | 577 | 0.050 |
Why?
| Pyrimidines | 1 | 2004 | 374 | 0.050 |
Why?
| Cell Division | 1 | 2003 | 754 | 0.050 |
Why?
| Lipids | 1 | 2004 | 564 | 0.050 |
Why?
| Chromatography | 1 | 2000 | 23 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 2 | 2005 | 1836 | 0.050 |
Why?
| Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 8 | 0.040 |
Why?
| Vaccination | 1 | 2008 | 1202 | 0.040 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 519 | 0.040 |
Why?
| Chemical Precipitation | 1 | 2020 | 37 | 0.040 |
Why?
| Injections, Spinal | 1 | 2020 | 101 | 0.040 |
Why?
| Complement System Proteins | 1 | 2023 | 281 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 315 | 0.040 |
Why?
| bcl-X Protein | 1 | 2020 | 38 | 0.040 |
Why?
| Electron Transport Complex IV | 1 | 2020 | 53 | 0.040 |
Why?
| Immediate-Early Proteins | 1 | 2020 | 52 | 0.040 |
Why?
| 3T3 Cells | 1 | 2000 | 140 | 0.040 |
Why?
| Herpesvirus 4, Human | 1 | 2020 | 124 | 0.040 |
Why?
| Ligands | 2 | 1998 | 557 | 0.040 |
Why?
| Viral Envelope Proteins | 1 | 2020 | 73 | 0.040 |
Why?
| China | 2 | 2010 | 161 | 0.040 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 140 | 0.040 |
Why?
| Ribonucleoproteins | 1 | 2000 | 85 | 0.040 |
Why?
| Up-Regulation | 2 | 2013 | 802 | 0.040 |
Why?
| Young Adult | 5 | 2014 | 10442 | 0.040 |
Why?
| Caspase 3 | 1 | 2020 | 234 | 0.040 |
Why?
| Carbocyanines | 1 | 2018 | 30 | 0.040 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 211 | 0.040 |
Why?
| Protein Conformation | 2 | 1998 | 803 | 0.040 |
Why?
| Biological Availability | 1 | 2018 | 119 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2000 | 205 | 0.040 |
Why?
| Permeability | 1 | 2018 | 149 | 0.040 |
Why?
| Solubility | 1 | 2018 | 223 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 23 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 87 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2014 | 1690 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2020 | 520 | 0.030 |
Why?
| Fluorescent Dyes | 1 | 2018 | 298 | 0.030 |
Why?
| Cell Adhesion | 1 | 1998 | 426 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2020 | 2321 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 301 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 725 | 0.030 |
Why?
| Antibodies, Monoclonal | 3 | 2008 | 1257 | 0.030 |
Why?
| Cattle | 1 | 2018 | 918 | 0.030 |
Why?
| Cell Communication | 1 | 2017 | 277 | 0.030 |
Why?
| Fetus | 1 | 2020 | 698 | 0.030 |
Why?
| Blood Proteins | 1 | 2017 | 222 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2007 | 181 | 0.030 |
Why?
| Lymphocyte Culture Test, Mixed | 2 | 2007 | 41 | 0.030 |
Why?
| Fibroblasts | 1 | 2020 | 834 | 0.030 |
Why?
| Protein Binding | 1 | 2000 | 1888 | 0.030 |
Why?
| Muscle Contraction | 1 | 1998 | 388 | 0.030 |
Why?
| Pharmaceutical Vehicles | 1 | 2014 | 11 | 0.030 |
Why?
| Cycloaddition Reaction | 1 | 2014 | 24 | 0.030 |
Why?
| Injections, Intravenous | 1 | 2014 | 198 | 0.030 |
Why?
| Chemistry, Pharmaceutical | 1 | 2014 | 98 | 0.030 |
Why?
| Fluorescence | 1 | 2015 | 148 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2014 | 110 | 0.030 |
Why?
| Membrane Proteins | 1 | 2000 | 1016 | 0.030 |
Why?
| Phosphatidylcholines | 1 | 2014 | 132 | 0.030 |
Why?
| Annexin A2 | 1 | 2013 | 10 | 0.030 |
Why?
| Tetraspanins | 1 | 2013 | 15 | 0.030 |
Why?
| Choline | 1 | 2014 | 106 | 0.030 |
Why?
| Copper | 1 | 2014 | 99 | 0.030 |
Why?
| Cross-Linking Reagents | 1 | 2014 | 179 | 0.030 |
Why?
| Metalloproteases | 1 | 2013 | 37 | 0.030 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2015 | 170 | 0.030 |
Why?
| Liposomes | 1 | 2014 | 146 | 0.030 |
Why?
| Particle Size | 1 | 2014 | 317 | 0.030 |
Why?
| Doxorubicin | 1 | 2014 | 286 | 0.030 |
Why?
| Coculture Techniques | 1 | 2013 | 198 | 0.030 |
Why?
| Surface Properties | 1 | 2014 | 385 | 0.030 |
Why?
| Feedback, Physiological | 1 | 2013 | 68 | 0.030 |
Why?
| Infant, Newborn | 1 | 2023 | 5038 | 0.030 |
Why?
| CD5 Antigens | 1 | 2012 | 8 | 0.020 |
Why?
| Pneumonia | 1 | 2017 | 563 | 0.020 |
Why?
| Ionomycin | 1 | 2012 | 24 | 0.020 |
Why?
| Drug Delivery Systems | 1 | 2014 | 295 | 0.020 |
Why?
| Antigens, CD1d | 1 | 2012 | 63 | 0.020 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 2012 | 151 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2012 | 132 | 0.020 |
Why?
| Cell Aggregation | 1 | 2011 | 24 | 0.020 |
Why?
| Antigens, CD19 | 1 | 2012 | 91 | 0.020 |
Why?
| Th1 Cells | 1 | 2012 | 123 | 0.020 |
Why?
| Prospective Studies | 2 | 2014 | 6195 | 0.020 |
Why?
| Phosphorylation | 2 | 2005 | 1558 | 0.020 |
Why?
| Interleukin-2 | 1 | 2012 | 413 | 0.020 |
Why?
| Time Factors | 1 | 2000 | 6077 | 0.020 |
Why?
| Adolescent | 3 | 2012 | 17798 | 0.020 |
Why?
| Monophenol Monooxygenase | 1 | 2008 | 8 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1791 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 192 | 0.020 |
Why?
| Interleukin-8 | 1 | 2009 | 229 | 0.020 |
Why?
| Radioimmunotherapy | 1 | 2008 | 11 | 0.020 |
Why?
| Genes, Insect | 2 | 1998 | 20 | 0.020 |
Why?
| Vaccines, DNA | 1 | 2008 | 29 | 0.020 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2008 | 61 | 0.020 |
Why?
| Immunotoxins | 1 | 2008 | 33 | 0.020 |
Why?
| Immunization, Passive | 1 | 2008 | 73 | 0.020 |
Why?
| Wings, Animal | 2 | 1998 | 32 | 0.020 |
Why?
| Vaccines, Subunit | 1 | 2008 | 41 | 0.020 |
Why?
| Down-Regulation | 1 | 2009 | 594 | 0.020 |
Why?
| S100 Calcium Binding Protein G | 1 | 2007 | 8 | 0.020 |
Why?
| Calbindin 2 | 1 | 2007 | 8 | 0.020 |
Why?
| Animals, Genetically Modified | 2 | 1998 | 215 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2013 | 1032 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2007 | 35 | 0.020 |
Why?
| Egg Proteins | 1 | 2007 | 19 | 0.020 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2007 | 26 | 0.020 |
Why?
| Hot Temperature | 1 | 2008 | 301 | 0.020 |
Why?
| Mutation | 3 | 2006 | 3338 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1128 | 0.020 |
Why?
| Ovalbumin | 1 | 2007 | 161 | 0.020 |
Why?
| Cytotoxicity, Immunologic | 1 | 2007 | 188 | 0.020 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 111 | 0.020 |
Why?
| Drug Synergism | 1 | 2007 | 315 | 0.020 |
Why?
| Transplantation, Isogeneic | 1 | 2006 | 17 | 0.020 |
Why?
| Antigen-Antibody Reactions | 1 | 2006 | 49 | 0.020 |
Why?
| Transplantation, Heterologous | 1 | 2006 | 180 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2007 | 266 | 0.020 |
Why?
| Dosage Forms | 1 | 2005 | 10 | 0.020 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2008 | 337 | 0.020 |
Why?
| Tocopherols | 1 | 2005 | 22 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2005 | 102 | 0.020 |
Why?
| alpha-Macroglobulins | 1 | 2005 | 24 | 0.020 |
Why?
| Ultrasonics | 1 | 2005 | 46 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 145 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 164 | 0.010 |
Why?
| T-Cell Antigen Receptor Specificity | 1 | 2004 | 41 | 0.010 |
Why?
| HeLa Cells | 1 | 2006 | 563 | 0.010 |
Why?
| Imatinib Mesylate | 1 | 2004 | 63 | 0.010 |
Why?
| Neovascularization, Pathologic | 1 | 2005 | 280 | 0.010 |
Why?
| Ependymoma | 1 | 2005 | 152 | 0.010 |
Why?
| Benzamides | 1 | 2004 | 168 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2005 | 1003 | 0.010 |
Why?
| Cell-Free System | 1 | 2003 | 47 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2272 | 0.010 |
Why?
| CD40 Antigens | 1 | 2003 | 81 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2009 | 2537 | 0.010 |
Why?
| Protein Folding | 1 | 2003 | 239 | 0.010 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2007 | 686 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2004 | 1117 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2006 | 1519 | 0.010 |
Why?
| Cell Differentiation | 1 | 2007 | 1695 | 0.010 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1356 | 0.010 |
Why?
| Pupa | 1 | 1998 | 10 | 0.010 |
Why?
| Genes, Lethal | 1 | 1998 | 26 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2001 | 613 | 0.010 |
Why?
| Crosses, Genetic | 1 | 1998 | 136 | 0.010 |
Why?
| Abdomen | 1 | 1998 | 99 | 0.010 |
Why?
| DNA, Complementary | 1 | 1998 | 255 | 0.010 |
Why?
| Larva | 1 | 1998 | 192 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1998 | 353 | 0.010 |
Why?
| Cytoplasm | 1 | 1998 | 255 | 0.010 |
Why?
| Muscles | 1 | 1998 | 320 | 0.010 |
Why?
| HIV Infections | 1 | 2010 | 2452 | 0.010 |
Why?
| Retina | 1 | 1998 | 263 | 0.010 |
Why?
| Base Sequence | 1 | 1998 | 2114 | 0.010 |
Why?
| Gene Expression Regulation, Developmental | 1 | 1998 | 801 | 0.010 |
Why?
| Risk Factors | 1 | 2006 | 8614 | 0.010 |
Why?
| Retrospective Studies | 1 | 2006 | 12520 | 0.010 |
Why?
|
|
Graner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|